• Vivani Medical won ethics approval from Australia’s Bellberry HREC to start SLIM-1, a Phase 1 trial of its NPM-139 semaglutide implant.
• Trial start targeted for mid-2026; open-label study compares low-dose implant versus Novo Nordisk’s Wegovy 0.25 mg/week for four weeks.
• Primary endpoints cover safety, tolerability, pharmacokinetics; weight loss tracked as an outcome measure.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vivani Medical Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606250730PRIMZONEFULLFEED9752468) on June 25, 2026, and is solely responsible for the information contained therein.